Jonathan Faison
Contributor since: 2011
Latest Articles
Kadmon Holdings: Revaluation Opportunity Still Intriguing
Intec Pharma: Lead Program Progressing, Continued Upside Ahead
Fate Therapeutics: Buy The Dip
Acadia Pharmaceuticals: Continued Upside Ahead Through Sales Growth And Clinical Catalysts
Caladrius Biosciences: Cheap With Catalysts On The Way
Krystal Biotech: Buy The Dip
Molecular Templates: Takeda News Provides Further Validation
Deciphera Pharmaceuticals: Will This ASCO Winner Repeat At ESMO?
Bellerophon Therapeutics: INOpulse Gets A Shot At Redemption
Affimed Therapeutics: Continued Upside Ahead
Celyad: Encouraging Progress In The Clinic Paving The Way For ASH Data
Reata Pharmaceuticals: Thesis Strengthened, Q3 Data Looms
ViewRay: Buy The Secondary
Magenta Therapeutics: This June IPO Should Be On Your Radar
Constellation Pharmaceuticals: A Recent IPO Of Interest
Scholar Rock: Value Waiting To Be Unlocked In This May IPO's Pipeline
Zafgen: This Revaluation And Catalyst Story Is Still In Early Innings
Checkpoint Therapeutics: Potential For A Near-Term Run Up
BioDelivery Sciences: Buy The Dip
Soleno Therapeutics: Rare Disease Pick With Significant Potential And Low Valuation
Savara: Buy The Secondary
uniQure: Buy The Dip
Applied Genetic Technologies Corporation: Near-Term Run Up Expected
Invuity: Turnaround In Progress
Viking Therapeutics: Thesis Strengthens, Catalysts In Focus
Arbutus Biopharma: Run Up Continues, Catalyst In Focus
ArQule: Continued Upside As Additional Catalysts Loom
Krystal Biotech: Data Due Year-End
Biotech: Take It On The Run
Zafgen Update: After Financing, Continued Revaluation Ahead
Gemphire Therapeutics: Financing Likely, NASH/NAFLD Opportunity In Focus
InflaRx: Buy The Dip